Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES2 | Q9H7Z7 | 8/20 | 0.70 |
| ▸ | ACLY | P53396 | 2/20 | 0.60 |
| ▸ | SGK1 | O00141 | 2/20 | 0.53 |
| ▸ | BRD4 | O60885 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | CCR4 | P51679 | 3/20 | 0.48 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1265337 | 0.84 | PTGES2 (0.64) | PTGES2ACLYSGK1SLC40A1 | |
| SCHEMBL2146366 | 0.84 | PTGES2 (0.61) | PTGES2ACLYSGK1BRD4CCR4 | |
| SCHEMBL3779083 | 0.83 | PTGES2 (1.00) | PTGES2BRD4ATMCCR4 | |
| SCHEMBL7852262 | 0.81 | PTGES2 (0.68) | PTGES2ACLYSGK1CCR4SLC40A1 | |
| SCHEMBL1265855 | 0.80 | PTGES2 (0.56) | PTGES2ACLYSGK1BRD4SLC40A1 | |
| SCHEMBL30897292 | 0.78 | PTGES2 (0.61) | PTGES2ACLYSGK1CCR4SLC40A1 | |
| SCHEMBL12407125 | 0.78 | PKM (0.54) | PTGES2SLC40A1 | |
| SCHEMBL1416034 | 0.78 | PTGES2 (0.51) | PTGES2ACLYSGK1BRD4CCR4 | |
| SCHEMBL14310492 | 0.78 | PTGES2 (0.51) | PTGES2ACLYSGK1BRD4CCR4 | |
| Hydrochloric Acid SCHEMBL31588089 | 0.77 | PTGES2 (0.60) | PTGES2ACLYSGK1CCR4SLC40A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099167-A1 | Organic compounds | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH | 2009-04-16 | — | — | US | disclosed |
| US-20090099167-A1 | Organic compounds | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH | 2009-04-16 | — | — | US | disclosed |
| US-20090069315-A1 | Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders | SIVASANKARAN RAJEEV | 2009-03-12 | — | — | US | disclosed |
| US-20090069315-A1 | Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders | SIVASANKARAN RAJEEV | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069315-A1 | Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders | EPHA5, EPHA7, EPHA1 | PTGES2 473/4885ACLY 4480/4885SGK1 1636/4885 |
| US-20090099167-A1 | Organic compounds | JAK1, MAP3K5, MAP3K7 | PTGES2 1774/4885ACLY 2769/4885SGK1 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.